A consortium led by state-owned pharma giant Sinopharm plans to take private China Traditional Chinese Medicine Holdings in a deal that would value the firm at least $3.3 billion, said two people with direct knowledge of the matter.
Sinopharm, China TCM’s parent and major shareholder, is teaming up with the next two biggest stockholders, Ping An Insurance Group Co of China and executive director Wang Xiaochun, said the people, with the three holding a combined 49.4% stake.